Fairvoy Private Wealth LLC Buys New Holdings in Illumina, Inc. $ILMN

Key Points

• Fairvoy Private Wealth LLC initiated a position in Illumina during the third quarter, purchasing 7,056 shares valued at approximately $1.93 million. Institutional investors collectively own 89.42% of the company.
• Illumina reported quarterly earnings of $1.31 per share, exceeding estimates of $1.23, while revenue rose 9.4% year over year to $1.16 billion. The company guided for fiscal 2026 earnings of $5.30–$5.40 per share.
• Director Keith Meister sold 457,858 shares for about $91.6 million, contributing to more than $436 million in insider sales over the past three months. Analysts remain mixed, with a consensus rating of “Hold” and an average price target of $231.88.

Fairvoy Private Wealth LLC bought a new position in Illumina, Inc. (NASDAQ:ILMN - Free Report) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 7,056 shares of the life sciences company's stock, valued at approximately $1,931,000.

Other institutional investors have also made changes to their positions in the company. Fiduciary Financial Advisors bought a new position in Illumina during the second quarter worth $26,000. MCF Advisors LLC boosted its holdings in Illumina by 172.4% in the second quarter. MCF Advisors LLC now owns 158 shares of the life sciences company's stock worth $28,000 after purchasing an additional 100 shares during the period. Keating Financial Advisory Services Inc. bought a new stake in Illumina during the second quarter valued at $32,000. Rakuten Securities Inc. bought a new stake in Illumina during the second quarter valued at $33,000. Finally, WealthCollab LLC increased its stake in Illumina by 51.5% during the first quarter. WealthCollab LLC now owns 303 shares of the life sciences company's stock valued at $37,000 after purchasing an additional 103 shares during the last quarter. 89.42% of the stock is currently owned by institutional investors.

Insider Activity at Illumina

In other news, Director Keith Meister sold 457,858 shares of the company's stock in a transaction dated Tuesday, August 4th. The shares were sold at an average price of $200.10, for a total transaction of $91,617,385.80. Following the completion of the transaction, the director owned 2,372,694 shares in the company, valued at approximately $474,776,069.40. This represents a 16.18% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders have sold a total of 2,061,850 shares of company stock worth $436,479,102 in the last three months. 2.90% of the stock is currently owned by corporate insiders.

Illumina Stock Performance

NASDAQ:ILMN traded up $0.12 during midday trading on Monday, reaching $262.66. 1,902,458 shares of the company traded hands, compared to its average volume of 2,175,622. Illumina, Inc. has a twelve month low of $94.00 and a twelve month high of $309.35. The firm has a market capitalization of $39.66 billion, a price-to-earnings ratio of 49.00, a price-to-earnings-growth ratio of 3.72 and a beta of 1.41. The company has a debt-to-equity ratio of 0.53, a current ratio of 1.80 and a quick ratio of 1.40. The company has a fifty day moving average price of $234.53 and a 200 day moving average price of $186.47.

Illumina (NASDAQ:ILMN - Get Free Report) last issued its earnings results on Thursday, July 30th. The life sciences company reported $1.31 earnings per share for the quarter, topping the consensus estimate of $1.23 by $0.08. The firm had revenue of $1.16 billion for the quarter, compared to analyst estimates of $1.13 billion. Illumina had a return on equity of 29.84% and a net margin of 18.36%. The firm's revenue for the quarter was up 9.4% on a year-over-year basis. During the same period last year, the company earned $1.19 earnings per share. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. On average, analysts expect that Illumina, Inc. will post 5.36 EPS for the current fiscal year.

Analyst Ratings Changes

ILMN has been the topic of a number of research reports. Guggenheim increased their target price on shares of Illumina from $226.00 to $305.00 and gave the stock a "buy" rating in a report on Thursday, October 1st. Evercore reaffirmed an "outperform" rating on shares of Illumina in a report on Monday, July 6th. Sanford C. Bernstein reaffirmed a "market perform" rating and set a $215.00 price objective on shares of Illumina in a research report on Friday, July 31st. JPMorgan Chase & Co. boosted their price objective on shares of Illumina from $220.00 to $230.00 and gave the company an "overweight" rating in a research report on Friday, July 31st. Finally, TD Cowen increased their price objective on shares of Illumina from $210.00 to $270.00 and gave the stock a "hold" rating in a research note on Tuesday, October 13th. Ten research analysts have rated the stock with a Buy rating, six have issued a Hold rating and two have given a Sell rating to the company. According to MarketBeat, the company presently has an average rating of "Hold" and a consensus target price of $231.88.

Illumina Company Profile

Illumina, Inc is a biotechnology company that develops and manufactures genomics and genetic-analysis technologies. Its products are used to study DNA and RNA in applications including biomedical research, clinical testing, pharmaceutical development, reproductive health, oncology and population genomics.

The company's offerings include next-generation sequencing systems, consumable flow cells and reagent kits, microarrays, and genomic data-analysis software. Its sequencing portfolio includes instruments such as the NovaSeq, NextSeq, MiSeq and iSeq platforms, while its informatics products include the DRAGEN platform, which supports the processing and interpretation of sequencing data.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.